New Strategies for Treatment of Sepsis.

antimicrobial stewardship emergency department immunomodulation intensive care internal medicine micronutrients organ dysfunction

Journal

Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208

Informations de publication

Date de publication:
10 Oct 2020
Historique:
received: 02 10 2020
accepted: 09 10 2020
entrez: 14 10 2020
pubmed: 15 10 2020
medline: 15 5 2021
Statut: epublish

Résumé

Sepsis represents a major global health concern and is one of the most feared complications for hospitalized patients, being the cause, directly or indirectly, of about half of all hospital deaths. According to the last definition, sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection and defined septic shock as a subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to significantly increase mortality. Sepsis is a time-dependent disease and requires a prompt recognition and a standardized treatment. The Special Issue "New Strategies for Treatment of Sepsis" has been thought to connect the experience of physicians involved in the diagnosis, management, and treatment of sepsis at every stage of disease, from emergency departments to general and intensive wards. The focus will be pointed on new approaches to this syndrome, such as early recognition based on clinical features and biomarkers, management in non-ICUs, non-invasive treatment strategies, including non-antimicrobial agents, and, of course, invasive approaches. This Special Issue will highlight the many different facets of sepsis, seen through the eyes of different specialists. We hope to spread the knowledge of a new blueprint for treatment.

Identifiants

pubmed: 33050538
pii: medicina56100527
doi: 10.3390/medicina56100527
pmc: PMC7599752
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Editorial

Langues

eng

Sous-ensembles de citation

IM

Références

JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
N Engl J Med. 2017 Aug 3;377(5):414-417
pubmed: 28658587
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Panminerva Med. 2020 Mar;62(1):54-62
pubmed: 31729202
Eur Rev Med Pharmacol Sci. 2019 May;23(9):4033-4043
pubmed: 31115033
Ann Med. 2017 Nov;49(7):582-592
pubmed: 28521523
Chin J Traumatol. 2020 Aug;23(4):190-195
pubmed: 32690231

Auteurs

Antonio Mirijello (A)

Internal Medicine Unit, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy.

Alberto Tosoni (A)

Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH